Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/NPM1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NPM1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NPM1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NPM1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/NPM1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NPM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/NPM1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NPM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/NPM1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NPM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NPM1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NPM1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NPM1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00448393 | Oral cavity | OSCC | cell cycle G2/M phase transition | 89/7305 | 148/18723 | 1.51e-07 | 2.51e-06 | 89 |
GO:00506869 | Oral cavity | OSCC | negative regulation of mRNA processing | 25/7305 | 29/18723 | 2.15e-07 | 3.43e-06 | 25 |
GO:00315034 | Oral cavity | OSCC | protein-containing complex localization | 123/7305 | 220/18723 | 2.54e-07 | 4.00e-06 | 123 |
GO:00320697 | Oral cavity | OSCC | regulation of nuclease activity | 20/7305 | 22/18723 | 6.02e-07 | 8.64e-06 | 20 |
GO:00510907 | Oral cavity | OSCC | regulation of DNA-binding transcription factor activity | 221/7305 | 440/18723 | 9.06e-07 | 1.23e-05 | 221 |
GO:00109483 | Oral cavity | OSCC | negative regulation of cell cycle process | 155/7305 | 294/18723 | 1.11e-06 | 1.48e-05 | 155 |
GO:190331220 | Oral cavity | OSCC | negative regulation of mRNA metabolic process | 58/7305 | 92/18723 | 2.59e-06 | 3.23e-05 | 58 |
GO:00435554 | Oral cavity | OSCC | regulation of translation in response to stress | 18/7305 | 20/18723 | 3.28e-06 | 3.92e-05 | 18 |
GO:004586016 | Oral cavity | OSCC | positive regulation of protein kinase activity | 194/7305 | 386/18723 | 3.90e-06 | 4.59e-05 | 194 |
GO:00900688 | Oral cavity | OSCC | positive regulation of cell cycle process | 126/7305 | 236/18723 | 4.75e-06 | 5.44e-05 | 126 |
GO:003311920 | Oral cavity | OSCC | negative regulation of RNA splicing | 21/7305 | 25/18723 | 5.07e-06 | 5.72e-05 | 21 |
GO:003367418 | Oral cavity | OSCC | positive regulation of kinase activity | 228/7305 | 467/18723 | 8.31e-06 | 8.90e-05 | 228 |
GO:003033018 | Oral cavity | OSCC | DNA damage response, signal transduction by p53 class mediator | 46/7305 | 72/18723 | 1.66e-05 | 1.64e-04 | 46 |
GO:00510917 | Oral cavity | OSCC | positive regulation of DNA-binding transcription factor activity | 134/7305 | 260/18723 | 2.52e-05 | 2.35e-04 | 134 |
GO:00480259 | Oral cavity | OSCC | negative regulation of mRNA splicing, via spliceosome | 17/7305 | 20/18723 | 3.21e-05 | 2.90e-04 | 17 |
GO:00435584 | Oral cavity | OSCC | regulation of translational initiation in response to stress | 13/7305 | 14/18723 | 4.31e-05 | 3.71e-04 | 13 |
GO:00094164 | Oral cavity | OSCC | response to light stimulus | 159/7305 | 320/18723 | 5.98e-05 | 4.92e-04 | 159 |
GO:00320706 | Oral cavity | OSCC | regulation of deoxyribonuclease activity | 10/7305 | 10/18723 | 8.14e-05 | 6.26e-04 | 10 |
GO:1902749 | Oral cavity | OSCC | regulation of cell cycle G2/M phase transition | 59/7305 | 102/18723 | 8.81e-05 | 6.72e-04 | 59 |
GO:19019895 | Oral cavity | OSCC | positive regulation of cell cycle phase transition | 65/7305 | 115/18723 | 1.03e-04 | 7.69e-04 | 65 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | Crizotinib | CRIZOTINIB | 27009859,25749034,24509625,18089725,25421750 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | IPP-204106 | | |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | N/A | | 19047294,26586702,16109776,26676635,26239249,25281355,24573385,25713434 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | AZD3463 | | 27009859 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | Deguelin | DEGUELIN | 25348016,25242579 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | Venetoclax | VENETOCLAX | |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | EPZ004777 | | 27535106 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | MI-503 | | 27535106 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | TRETINOIN | TRETINOIN | 19965647,21719597 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | Midostaurin | MIDOSTAURIN | |